miR-21在乳腺癌患者血清中的表达及意义

目的检测乳腺浸润性导管癌患者血清miR-21的表达水平并探讨其临床意义。方法选取自2012年3月-2013年7月于笔者医院就诊乳腺疾病女性患者共49例作为研究对象，其中乳腺良性肿瘤组23例，乳腺浸润性导管癌组26例（I期9例、Ⅱ期11例、Ⅲ期6例），应用实时荧光定量（qRT）-PCR检测血清中miR-21的表达水平，并分析血清miR-21的表达与乳腺浸润性导管癌临床病理因素之间的关系。结果乳腺浸润性导管癌组检测的血清miR-21浓度明显高于乳腺良性肿瘤组，血清miR-21的表达增高与TNM分期、淋巴结转移呈正相关。结论血清miR-21在乳腺癌患者血清呈高表达，并与其病理学分级、淋巴结转移密切相关。

Expression of miR-21 in Serum of the Breast Cancer Patients.

Objective To observe the expression of serum level of miR - 21 in breast invasive ductal carcinoma for identifying its clinical significance. Methods The expression of miR - 21 in serum sample of 49 cases from Mar 2012 to July 2013, 23 cases of benign breast lesions, 26 cases of breast cancer （9 cases at stages I , 11 cases at stages Ⅱ , 6 cases at stages Ⅲ） was detected by real - time fluorescence quantitative PCR. The correlation between expression of serum level of miR -21 and the clinicopathogical features of breast carcinoma were analyzed. Results The serum level of miR - 21 in breast invasive ductal carcinoma was higher than benign breast le- sions. High serum miR - 21 expression was associated with advanced stage and Lymph nod metastasis. Conclusion The high level of se- rum miR - 21 may contribute to the pathogenesis and development Lymph nod metastasis of breast cancer.